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Anil Gumber
Bhanu Ramaswamy
Oranuch Thongchundee
Faculty of Health and Wellbeing, Shefﬁeld
Hallam University, Shefﬁeld S10 2BP, UK
Background: Parkinson’s is an incurable, neuro-degenerative condition with multiple
symptoms substantially impacting on living conditions and quality of life (QoL) for people
with Parkinson’s (PwP), most whom are older adults, and their families. The study aimed to
undertake a literature review of studies conducted in the UK that quantify the direct or
indirect impact of Parkinson’s on people with the condition, their families, and society in
terms of out-of-pocket payments and ﬁnancial consequences.
Methods: Literature was searched for Parkinson’s-related terms plus condition impact (eg,
ﬁnancial, employment, pension, housing, health care costs, and QoL) in the UK setting. The
strategy probed several electronic databases with all retrieved papers screened for relevancy.
The instruments used to measure patient-related outcomes were then examined for their
relevancy in justifying the results.
Results: The initial search retrieved 2,143 papers of which 79 were shortlisted through title
and abstract screening. A full-text reading indicated 38 papers met the inclusion and quality
criteria. Summary data extracted from the articles on focus, design, sample size, and
questionnaires/instruments used were presented in four themes: (a) QoL and wellbeing of
PwP, (b) QoL and wellbeing of caregivers and family members, (c) employment and living
conditions, and (d) direct and indirect health care and societal cost.
Conclusion: UK results substantiated global evidence regarding the deterioration of QoL of
PwP as the condition progressed, utilizing numerous measures to demonstrate change. Many
spouses and family accept care responsibilities, affecting their QoL and ﬁnances too. The
review highlighted increased health care and privately borne costs with condition progres-
sion, although UK evidence was limited on societal costs of Parkinson’s in terms of loss of
employment, reduced work hours, premature retirement of PwP and caregivers that directly
affected their household budget.
Keywords: Parkinson’s, HRQoL, wellbeing, employment loss, health care cost, societal cost
Introduction
Parkinson’s, a long-term condition with more than four-ﬁfths of those affected over 60
years of age, is diagnosed through clinical investigations of movement quality (from
the reduced manufacture of the neurotransmitter dopamine), causing classic motor
(movement) symptoms of slowness (bradykinesia), stiffness (rigidity), and tremor.1,2
People with Parkinson’s (PwP) also experience non-motor symptoms such as depres-
sion, fatigue, and pain that manifest before many of the motor features.3 There is no
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cure for the condition, but early diagnosis can help in
enabling the person to manage their varied symptoms
through support from health professionals, voluntary ser-
vices, carers, and family.4
Of the estimated 137,000 PwP1 in 2015 in the United
Kingdom (UK), prevalence rates are higher in males, with
an exponential increase in both men and women beyond 60
years of age,5,6 but not varying signiﬁcantly by level of depri-
vation and geography in the UK.5,7 The expected rise of PwP
to 169,000 by 20251 in the UK means health and social care
provision to addressmanagement and carewill be challenging,
especially in the face of an aging population. The likely impact
is an enormous cost to individuals, Government, and society.
Both motor- and non-motor symptoms develop during
different times over the course of the progressive condi-
tion, require diverse strategies and resource inputs. With
the estimated increased cost of management is likely to
impose substantial detrimental effects on quality of life
(QoL). As most Parkinson’s care is informal, this impact
will extend further than the PwP, encompassing carers,
family, friends, and relatives.8 It is essential to understand
the current cost of care, management, and effective treat-
ments for those affected by Parkinson’s and to UK society.
To this effect, the systematic literature review gathered
evidence on the impact of Parkinson’s on the socio-economic
life of PwP, their families, and society based on prior UK-
based research. The study sought to improve our understand-
ing of the key components of direct and indirect health care
costs associated with Parkinson’s management and care.
Methods
Inclusion criteria
Peer reviewed papers, published in the English language,
reporting qualitative or quantitative UK data or
gray literature which underpinned and quantiﬁed the direct
and indirect impact of Parkinson’s on PwP, their families,
and society were considered.
Search strategy
The research team established a literature search strategy
comprising component terms for: (1) Parkinson’s, (2) con-
dition cost-associated descriptions, eg, ﬁnancial, employ-
ment, pension, housing, health care costs, and QoL, and
(3) UK-based studies. All terms were searched for in the
title and abstract ﬁelds, with controlled vocabulary usage
as appropriate and available. Boolean operators AND and
OR were used, alongside truncation, phrase searching and
proximity operators. Papers were exported from ASSIA
(ProQuest), CINAHL (EBSCO), Cochrane Library
(Wiley), EMBASE (via National Health Service
Healthcare databases), MEDLINE (EBSCO), and Web of
Science (Thomson Reuters) into RefWorks (a biblio-
graphic management tool).
Quality appraisal and study selection
Following removal of duplicates using RefWorks, 2,143
papers were obtained, and their titles and abstracts were
screened for relevancy. The 79 shortlisted papers were
subjected to a full-text scrutiny by two members of the
research team, with a ﬁnal selection of 37 papers. The
included full-text papers were subjected to a quality check-
list to maintain validity, quality, and to limit the probability
of any bias. Whilst most of these studies were non-
randomized clinical trials, we followed a simpliﬁed apprai-
sal tool9 to assess their quality on the basis of study aims,
methods, sampling, data analysis rigor, ethics and bias,
ﬁndings, and their generalisability. The 42 articles
excluded at this stage were rejected on the basis that
seven were duplicates, four were prevalence studies of
Parkinson’s and Parkinsonism, ﬁve were descriptive,
eight were conference abstracts, ten were non-UK based,
ﬁve were letter/advocacy papers, and three focused on
validating scales/questionnaires. The search and screening
process adapted from The PRISMA Group is summarized
in Figure 1.
Data extraction and synthesis
Papers were read and data reviewed using a standardized
extraction form encompassing: author/date, the focus of
the study, research design, sample size, and questionnaires/
instruments employed. The information was categorized
into four themes: (a) QoL and wellbeing of PwP, (b) QoL
and wellbeing of caregivers and family members, (c)
employment and living conditions, and (d) direct and
indirect health care and societal cost. For each category,
the measures that demonstrated change were then consid-
ered in terms of how they added to this review’s aims.
Studies included for review
A majority of the articles included in the literature review
investigated the impact on the QoL of PwP (16 papers),
and/or QoL and wellbeing of the caregivers and family
(nine papers), most of who were spouses. Ten papers
estimated direct or indirect health care costs related to
Parkinson’s, and just four studies focused on the impact
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on their employment and living conditions. Individual
study topics, type, sample size, and questionnaires/instru-
ments used in the studies are summarized in Tables 1–4.
Gray literature search
This was undertaken through a National Institute for Health
and Care Excellence (NICE) Evidence Search and on
Google. Gray literature inclusion is aligned with the compre-
hensive review methodology previously outlined, plus helps
to minimize the risk of publication bias. The search used an
abridged set of terms (restricted by the resources character
limits), with salient literature yielded scanned, much of
which was duplicated in the electronic database search. One
study was found to be relevant for inclusion in the review.
Main ﬁndings from UK studies
QoL and wellbeing of PwP
The impact on QoL and wellbeing of PwP as the condition
progressed was noted from changes to both motor and non-
motor symptoms in 16 studies (Table 1). These were separated
into two groups based ﬁrstly on the severity and diversity of
symptoms, and secondly on self-help group and social support
and their interface with their health and wellbeing.
To investigate the wide-ranging symptoms, the means of
obtaining results from the individual papers came from
a varied selection of methods such as thematic analysis
from interview methods, and measurement instruments
such as self-ﬁlled and researcher administered question-
naires, asking about general health state, or speciﬁc aspects
such as sleep quality, mood, disability, and adjustment.
Some were condition speciﬁc and some generic, plus there
were validated questionnaires or researcher-developed tools
speciﬁc to their study requirements (Table 1).
Differential effects of symptoms with stages of
Parkinson’s
The type of symptoms and their severity varied over the
disease progression; however, started worsening in those diag-
nosed over 6 years.10 QoL deteriorated regardless of whether
the experience was motor or non-motor, with anxiety-related
Papers screened by title (and abstract were 
necessary)
(n = 2143)
Papers identified through database searching 
(n = 3046)
Papers after duplicates removed 
(n = 2143)
Abstract and full-text papers screened for 
eligibility (n = 79)
Papers included in this review 
(n = 37+1 gray literature search)
Papers excluded 
(n = 42)
Papers excluded due to following 
reasons: seven duplicates, four on 
prevalence, five descriptive in 
nature, eight conference abstracts, 
ten non-UK based studies, five 
letter/advocacy papers, three 
focused on validating 
scales/questionnaires
Papers excluded 
(n = 2065)
Figure 1 The PRISMA ﬂowchart of literature review selection process.
Note: Adapted from Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting Items for systematic review and meta-analyses: the PRISMA
Statement. PLoS Med. 2009;6(6): e1000097.65
Dovepress Gumber et al
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reasons associated with anticipated deterioration, a large factor
affecting QoL. Ten of the 16 papers used a version of the
Parkinson’s Disease QoL Questionnaire (PDQ-39) covering 8
Parkinson’s-related domains (mobility, activities of daily liv-
ing (ADLs), emotional wellbeing, stigma, social support, cog-
nition, communication, and bodily discomfort)11 to measure
health-related QoL (HRQoL) in PwP.
Motor symptoms
Mobility difﬁculties affecting walking and turning, with con-
sequences of falling, inﬂuenced costs related to injury and
increased time in the hospital, and impeded involvement in
social activities. Motor symptoms signiﬁcantly inﬂuenced
QoL scores with lower HRQoL reported in PwP.12 A study
in Scotland found the QoL of PwP who attended a movement
disorders clinic as compared to a general medical clinic to be
signiﬁcantly higher and better.13
Non-motor symptoms
Non-motor symptoms are problematic in that they are experi-
enced as distinct symptoms ranging from pain, mood, cogni-
tion, sensory, and autonomic disturbances, worsening with
advancing age and Parkinson’s severity. The impact on
HRQoL of PwP spans early to advanced stages of the condi-
tion, with depression, anxiety, impaired concentration, mem-
ory retrieval, sleep disturbance, and autonomic disturbance, all
negatively impacting on QoL.10,12,14–17 Depression was found
in at least 50% of PwP, worsening with condition progression
yet despite the presence of this non-motor symptom, it was
largely under-recognized and was ineffectively managed.10
A consequence of depression (measured through a HRQoL
tool, the EQ-5D18), was seen as reduced health-state value at
a very early stage of the condition, whilst motor impairment,
insomnia, and pain affected the health-state value of PwP at
a later stage of the condition.19
Unlike depression, pain was ranked highly by PwP in
a survey of the three most troublesome symptoms they experi-
enced, even at an early stage following the diagnosis, and
consequently negatively affecting their QoL and contributing
in raising both direct medical and other health care cost.10
Self-help groups and social support in PwP
To participate in life includes engagement in thewider sense of
managing self-care as well as productive (economic) and lei-
sure occupations, something PwP have difﬁculties with.20
From a semi-structured interview with PwP, it was learned
that they perceived and managed the experience of living
with Parkinson’s as “change”, “addressing changes”, and
“reﬂections on living with Parkinson’s”.20 “Change” described
the expectedmotor and non-motor symptoms experienced, but
also a loss of employment, and gains in new skills due to being
diagnosed with Parkinson’s. By “addressing changes”, partici-
pants included their management of medications and involve-
ment of others in their lives as Parkinson’s progressed, what
they did to stay well and how they found different ways to do
things. In terms of “reﬂections on living with Parkinson’s”,
people explored encounters with others and their own accep-
tance of the condition, stressing the importance of attitude
(positive) and maintaining “life as usual”. Belonging to self-
help groups (although there was room for them to be more
supportive), and having strong social support (including close
relationships), helped PwP accept the condition and adapt their
lifestyle.21,22 Whilst all PwP described the loss in terms of
physical and mental functioning and independence, self-
identity, and the fear of future losses with the progression of
the condition,22 those with having wide support reported rela-
tively better psychological outcomes than PwP socially unsup-
ported, who recorded higher levels of distress, anxiety and
stress, and lower life satisfaction.21
For research purposes, Parkinson’s is rated according to the
5-stage disease rating scale,23 where Hoehn and Yahr (H&Y)
stage 3–5 relate to the later stages of Parkinson’s. As QoL
deteriorates in these later stages of Parkinson’s, end of life
support needs arise, especially if the person lives alone, or for
a large number of people who become less physically mobile.
Over two-thirds of PwP are considered to have a severe dis-
ability, with more than one-third becoming wheelchair or bed-
bound,24 with the reduction in QoL noted in these patients
(using the EuroQol-5D [EQ-5D]18 and PDQ-825 question-
naires) from the severity and complexity of their experienced,
and untreatable non-motor and motor symptoms.
Strong social networks and close relationships become
important for younger PwP, whose responses recorded lower
QoL and emotional wellbeing than the older PwP, possibly due
to their perception of stigma and psychosocial consequences
including lower mood.26,27 Support received has to be per-
ceived as desirable, and where the condition forces people into
unwelcome choices, the QoL is negatively affected. This was
clearly demonstrated by a study of the subjective wellbeing of
PwP living in a care home, which was lower than in people
living alone in their own home.28 Further, PwP living at home
with a reduced ability to perform a chosen occupation of daily
living reported poorer physical, psychological, social, and
spiritual wellbeing; some of them affecting their employment
and experienced distress and disappointment and thus reported
deterioration in their QoL and wellbeing.29
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QoL and wellbeing of caregivers and
family members
Parkinson’s also affects the QoL of caregivers, which
often was assessed using the condition-speciﬁc PDQ-
carer questionnaire.30 Some studies used more generic
questionnaires for measuring QoL of caregivers, eg,
Short form (SF)-12 questionnaire to measure physical
and mental health31 or self-reported wellbeing questions
(Table 2). Several factors inﬂuence carer’s QoL including
age (mean age ranging 68–72 years), gender (most being
female spouses), health status, duration of caregiving role,
the level of mobility, and cognitive function in PwP.
Caregivers had a co-morbidity rate nearly ﬁve times
greater when compared to the age-matched population,
particularly where the PwP they lived with had psychiatric
symptoms, with a comparable reduction in QoL over time
in social, anxiety and depression, stress, and self-care
measures affecting the social, psychological, and physical
wellbeing of carers.32–37 Once falling occurred in PwP, it
had a signiﬁcant impact on carer’s QoL by increasing
anxiety, worry, fear, anger, frustration, and shock, restrict-
ing their normal activities (indoors and outdoors), and
their contact with friends and neighbours.32,38 There was
too a ﬁnancial impact of increasing health care costs for
PwP and caregivers as falls occurred.32
Where the impact of Parkinson’s on other family mem-
bers, including offspring was studied, assisting in ADL,
plus a reduction in social life were the main complaints of
adolescent children of PwP.40 For adult children, there was
the additional stress of caring for their own family affect-
ing QoL and wellbeing, with similarities noted in children
of all aged of parents with either Parkinson’s or Multiple
Sclerosis.41 The NICE guidelines for Parkinson’s disease
published in 2006 and updated in 201742,43 makes no overt
reference to the children of PwP although many children
providing informal care to PwP expressed an issue with
the lack of information about their parents’ condition.40,41
Employment and living conditions
The four studies on the ﬁnancial implications of
Parkinson’s examined results from previously conducted
surveys, the use of researcher-decided questions, and
a semi-structured interview (Table 3).
Full-time or part-time working was affected for PwP,
with a reduction in employment for those in the later stages
of the condition. From a review of patient surveys of PwP
diagnosed more than 5 years, 6–10% were working full
time, 7% part-time, and 46% were unable to work, with
this percentage increasing to 82% after more than 10 years
post-diagnosis.44 The same survey identiﬁed the average
time lost from employment due to Parkinson’s symptoms
to be 4.9 years, with gender, type of work, and living
circumstances exerting a minimal inﬂuence on this ﬁgure.44
An assessment of the QoL and care of PwP attending
movement disorders clinic in England, found the main pro-
blems with care related to accommodation, travel, holidays,
and hobbies, with forced early retirement and waiting for
welfare beneﬁts worsened ﬁnancial difﬁculties in PwP.45
Employment conditions altered for carers too, adding
to their stress.37 One-fourth of carers had to reduce their
working hours to care for someone with Parkinson’s and
30% endured a reduction in ﬁnancial status,37,46 also
resulting in problems accessing state welfare beneﬁts.46
Direct and indirect health care and
societal cost
The overall household economic burden of Parkinson’s
was assessed through measurement of direct medical, non-
medical costs, and indirect costs utilizing varied question-
naires on resource use (household and health), linking
them to measures of QoL, Parkinson’s staging, health,
cognitive and disability states (Table 4).
Resource use data recorded the range of annual costs of
the condition from £13,80047 to £29,000,48 with direct
medical costs of £1,881 per patient per annum for hospi-
talization, clinic appointments, and investigations. Indirect
costs from informal care by family members, lost produc-
tivity and sickness ranged between £11,000 and
£12,500 per person per annum.47,48 Of total care costs,
80.3% was “spent” as total informal care costs, whilst
direct social cost was just 5%.47
The economic and ﬁnancial strain impacted on QoL of
both PwPs and carers, with most of the latter being retired
and are female spouses of more male population with
Parkinson’s, with underestimated costs (time and effort)
underwritten by carers.47 For PwP, QoL was affected by
their response to medication cycles and hence to symptom
severity (worse in those with higher H&Y scores), with
degraded symptoms, particularly to movement experienced
in the “off” state (when medication to improve movement
was not optimal), which resulted in rising costs with the
longer duration since Parkinson’s diagnosis, incidence of
depression, gait disturbance, and privately borne commu-
nity-related costs.48 The projected total cost of Parkinson’s
Gumber et al Dovepress
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per year was put between £450 million to over £3 billion,
with the difference accounted for by privately funded indir-
ect costs, and prevalence rates for Parkinson’s according to
the economic modeling used.49
Hospital admissions data placed elective admission for
PwP at 28% of the health costs and 72% non-elective
admission when compared to age and sex-matched popu-
lation utilizing 60% and 40% of the total hospital costs.50
Excess bed days utilized 12% of the total costs50 from
admissions related to infection, Parkinson’s or cardiac-
related symptoms, with falls and hip fractures resulting
in higher admission rates and costs.50 In addition to falls
being a signiﬁcant factor affecting QoL, co-morbidity in
PwP resulted in more frequent emergency admissions and
longer hospital stays, and for those over 85 years, in
increased mortality than in younger PwP.50,51
Non-medical services in the community and hospital
appointments, such as that provided by the Parkinson’s
Disease Nurse Specialist (PNS) saved expenditure on
Parkinson’s care, with an estimated annual cost savings
of nearly £55,000.52 Whilst PNS intervention was not
found to impact on the clinical condition of PwP, indivi-
duals reported an improvement in their wellbeing from the
support.53,54
PwP accessed health and social care provision, whether
living in institutional care or in their own home. The latter
utilized domestic home care or personal (family provided)
services, as well as community health service provision
from professionals or attendance to a local day care
center.55 Progression of the condition measured by H&Y
score had a direct impact on health and social care costs,
with the lowest costs at diagnosis (£2,971 per person)
compared to at H&Y stage 5 (£18,358).56 Accommodation
type affected costs, with people living in their own home
utilizing services at a cost of £4,189 compared to indivi-
duals in an institutional setting who utilize services at an
almost ﬁvefold higher cost.56
Discussion
Investigating health and the consequences of ill health is
complex and so is about the impact on the QoL and well-
ness. Measurement of health and wellness has to take into
account individual perceptions, each of which will differ
according to cultural understanding and societal contexts,
including personal expectations of subjective wellbeing
eg, happiness, plus ﬁnancial, and environmental
stability.57 From the health perspective, research is
designed to inﬂuence the population as a collective, as inTa
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the Public Health environment, yet then rationalized to
individual management by the clinician.
For a condition such as Parkinson’s, the complexity
crosses a wide range of issues, ever-changing as the con-
dition progresses.10,17,19 The motor symptoms, affecting
movement, and non-motor symptoms, affecting mood,
sleep, cognition, and bodily function can be measured to
quantify their presence, and linked to aspects of the stage
a person is at,10,11,15,16,18,23 but also to the impact of those
providing support.33–41
Evidence from the articles in this review was interpreted
from multiple methods of information and data gathering
(see “Instruments” column in Tables 1–4), with the different
measures capturing the diverse aspects of this condition.12,58
The resultant comparisons acknowledged the broad impact
on the PwP and their support network, of immediate family
and carers, identiﬁed in the four themes providing an under-
standing of how Parkinson’s affects the economic, social,
ﬁnancial, health, and living conditions.
A measuring tool should be chosen on the basis it
could encapsulate the researcher’s expectation of change
from intervention or description of a situation.58 It is now
standard practice to reﬂect patients’ views of their position
with a medical condition when designing and validating
a measurement tool.59
The papers in this review gathered information through
qualitative means (mainly from interview methods); self-
ﬁlled questionnaires, whether condition speciﬁc eg PDQ-
39 or generic eg, EQ-5D, depression or stress scales;
professionally ﬁlled condition-speciﬁc and generic ques-
tionnaires, again many around cognition and mood; pro-
fessionally ﬁlled subjective scales to place the person
along the course of the condition eg H&Y Stage scale;
and researcher-developed tools speciﬁc to a study.
Many of the instruments were canvassed to small
numbers of participants and reviewed broad aspects of
their Parkinson’s impact, or use standardized questions
providing only a glimpse into the life for people at
a particular stage of this progressive and variable
condition.60 Yet the validity of some papers cannot be
discounted on this basis, as they measure what the papers’
aims state they wish to quantify.58
For example, from Table 1 alone, several papers utilize the
condition-speciﬁc PDQ-39 or PDQ-8 questionnaires to record
the HRQoL in PwP.12–15,17,21,24,26,27 The PDQ-39,11 and
shorter version PDQ-825 are categorized according to eight
domains identiﬁed from a survey with PwP about issues
affecting their QoL. These measures provide a snapshot into
the lives of people by rating the person according to medically
deﬁned Parkinson’s-speciﬁc scales through the use of the
H&Y disease stage scale23 or the Uniﬁed Parkinson’s
Disease Rating Scale,61 a scale of subjectively recognized
and medically assessed symptoms. Although this version of
the scale has been updated to a more patient-involved tool, the
new version is not widely used yet.
Opinions of PwP have been sought in varied ways
from the request to complete a booklet with several dif-
ferent questionnaires listing aspects from mobility to
depression and anxiety for the PwP to rate;12 a survey of
freely chosen and ranked three most troublesome symp-
toms affecting the QoL of the people who attended
clinics,10 to the researchers quantifying symptoms such
as reported ADL or evaluation of disability.14 The majority
of the tools, however, are still presented as numerical
scales, or based on subjective decisions of the medical
professional or researchers. Categorizing information on
behalf of PwP is questionable in terms of the meaningful-
ness of the responses.62
The qualitative paper authors strove for a process and
outcomes of relevance to the speciﬁc people participating in
the research. For example, in Benharoch and Wiseman’s phe-
nomenological approach,20 the semi-structured interviews of
PwP are used as a basis from which to guide the interview,
thus following issues the participants raised as important to
them. Where semi-structured interviews were undertaken by
Barrow and Charlton,22 the chosen questions were initially
developed through pilot discussions from people in the types
of groups they would then go on to interview.
The tools and methods of gathering information in the
review articles neither permit clear relational interpretation
nor differentiate person-speciﬁc issues eg, problems in
coping with treatment or self-management. The wide-
ranging approaches do not identify the construction of
categories that inﬂuence the QoL of PwP, factors such as
employment, or the costs of the condition to themselves
and across society. There was also lack of reporting of
incidence and prevalence of Parkinson’s by the individual
UK home countries especially Northern Ireland.
Yet what is seen are patterns from the UK evidence
suggesting that Parkinson’s management and care respon-
sibility has fallen on spouses and extended family mem-
bers of PwP directly affecting QoL, wellbeing, and
ﬁnancial status. Where QoL in PwP deteriorated as the
condition progressed (particularly as non-motors symp-
toms including sleep disorders and depression increased
over time), the impact was experienced in rising stress and
Gumber et al Dovepress
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fatigue level among carers with incidences such as falls in
PwP identiﬁed as the most signiﬁcant factor impacting on
both caregiver’s and PwP social life and wellbeing. The
frequent occurrence of falling lessened the chances for
caregivers to go out for their normal activities and conse-
quently decreased their contact with friends and
neighbours.
The challenging role of caregivers often goes unrecog-
nized. Spouses acting as informal carers are also aging with
their own health problems, whilst adapting to reduced inde-
pendence, increased social isolation, physical exhaustion, and
psychological stress. That carers’ burden, which is a major
source for economic and ﬁnancial cost, has not been factored
into cost-effectiveness analyses.63 Recognition of this would
ensure better assessment of carers’ needs and respite provision
to help in sustaining their efforts and energy for continued care
to PwP, thus improving HRQoL of carers.63
Although not reviewed across the course of Parkinson’s,
the UK-based evidence suggests a more than double increase
in total annual costs of Parkinson’s per case, from 2006
(£13,800) to 2011 (£29,000). Non-medical costs, including
informal care accounted for the majority of the expenses,
whilst health care cost was the greatest due to unplanned
hospital admissions for PwP and their extending length of
hospital stay compared to the general population.
There was evidence of loss of employment, reduced
work hours, premature retirement of both PwP and care-
givers, worsening according to condition progression after
5 years post-diagnosis, with time off work also noted after
this timeframe. Parkinson’s created ﬁnancial difﬁculties
from forced retirement and delays in receiving welfare
beneﬁts. No UK-based study looked comprehensively at
how Parkinson’s affected employment or working condi-
tions of carers, including private expenditure to maintain
household living standards.
Conclusion
Deterioration of QoL of both the PwP and caregivers as
the condition progresses puts a tremendous economic and
ﬁnancial burden on the household of the PwP and society
in terms of social care and health care delivery costs.
The incurable and long-term nature of this neuro-
degenerative condition creates multi-factorial and complex
symptoms which have a substantial impact on QoL, more so
as the condition progresses, and particularly as an individual
becomes less able to look after him or herself. Parkinson’s
care tends to be provided informally, as family members and
friends take on a carer role to assist the PwP, with more cost
of managing Parkinson’s attributed to informal and social
care, rather than direct medical costs. The literature high-
lights deterioration in QoL of PwP plus their carers and
family members over time, both in economic and social
terms. Whilst evidence is limited in assessing income loss
from changes in employment to the households of PwP, as
well as out-of-pocket expenditure incurred in accessing both
health and social care services, it is shown that family mem-
bers volunteer time, alter employment status and utilize their
own resources, developing stress and health problems along-
side the deterioration of the person they care for, thus accent-
uating the total societal costs.
The literature highlights the critical role of the support
services (especially the PNS) in the management and care
of the condition, reiterating a need for provision that
strengthens and extends services to PwP and their families.
Crucial gaps were identiﬁed in the existing evidence by
various stakeholders for addressing everyday practicalities
in the management of the complexities of Parkinson’s;
a priority for Parkinson’s research agenda.64
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